Wed, Mar 4, 2015, 10:39 AM EST - U.S. Markets close in 5 hrs 21 mins


% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

bertrand1234 1 post  |  Last Activity: Jan 8, 2015 4:58 PM Member since: Jan 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by bertrand1234 Jan 8, 2015 4:58 PM Flag

    I read the whole presentation and most of it looks pretty good. I didn't have time to listen to the CC due to work. The ONLY thing that I can't see going well (possibly) is the whole issue with the liver disease and decreased drug uptake. I have a PhD in pharmaceutical sciences so I'm pretty familiar with the data, but this still stumps me. My logic is as follows:

    1. They are trying to teach people with severe liver disease. However, the more severe the liver disease, the less drug is getting into the liver according to the data.
    2. I don't see how increasing the dose will increase the amount of drug in the least it doesn't seem like it would be a lienar relatoinship. They already show that with more severe liver disease, a TON of more drug isn't absorbed and remains in the blood stream. More drug would just result in more drug in the blood stream and not necessarily more getting into the liver. My guess is that any beneficial effect may be saturable when the disease has progressed to far.

    Did they address this at all in the CC? Any other input would be well appreciated. Otherwise, I'm very positive about their technology platform.

68.80+0.14(+0.20%)10:38 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.